T Bio LLC. IT (Immune Therapy) Bio was founded in 2018 with long-term objective to develop advanced generation “designer” CAR-T for HIV therapies. In parallel, we are developing technology to improve checkpoint receptor therapy in cancers.
Our mission is to design novel anti-exhaustion therapies to improve treatments against cancers and chronic viral infections
Our risk of cancer increases significantly after age 50, and half of all cancers occur at age 66 and above. Our expertise ranges from the lab bench to the bedside. We are even studying the impact of chemotherapy as a driver of secondary cancers.
The focus area of research at IT Bio is to explore and design therapies to target T cell dysfunction in cancer and chronic viral infections. A hallmark of terminal T cell exhaustion is the upregulation of Checkpoint Receptor (CR) axis and downregulation of Cytokine axis. With perturbation of these two Axes, T cells infiltrating immunogenic tumors become dysfunctional. Research over the years has shown that by addressing therapeutically these two Axes of Exhaustion, T cells can reverse aspects of functional decline, ultimately restoring killing activities. Clinically, however, the CR axis of checkpoint receptor blockade (CRB) interventions has attracted the most attention due to success in eradicating previously intractable stage III and IV cancers. Still, only 20% to 40% of patients respond to single agent CRB, while >50% of patients exhibit tumor progression. The failure to address concurrently the Cytokine axis may be cause for the limited response rates versus what might otherwise be possible. We have demonstrated that that pharmacologic treatment with Ezh2 inhibitors restored IL2 production in clinical grade anti-CEA CART cells that reversed CAR-T exhaustions. Our results demonstrate that anti-PD1 therapy when combined with pharmacologic inhibitor caused inhibition of tumor growth in syngeneic mouse model compared to single agent therapy as well as improved survival rate.
CONTACT
General Inquires: info@itbiollc.com
ADDRESS
IT Bio, LLC
One Lyndeboro Place
Boston, MA 02116